BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1547881)

  • 1. A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia.
    Kloke O; Wandl U; Opalka B; Moritz T; Nagel-Hiemke M; Franz T; Becher R; Hirche H; Seeber S; Niederle N
    Eur J Haematol; 1992 Feb; 48(2):93-8. PubMed ID: 1547881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.
    Niederle N; Kloke O; Wandl UB; Becher R; Moritz T; Opalka B
    Leuk Lymphoma; 1993 Jan; 9(1-2):111-9. PubMed ID: 8477190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemia.
    Wandl UB; Kloke O; Nagel-Hiemke M; Moritz T; Becher R; Opalka B; Holtkamp W; Bartels H; Seeber S; Niederle N
    Br J Haematol; 1992 Aug; 81(4):516-9. PubMed ID: 1390238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.
    Cortes J; Kantarjian H; O'Brien S; Robertson LE; Pierce S; Talpaz M
    Am J Med; 1996 Apr; 100(4):452-5. PubMed ID: 8610733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma.
    Opalka B; Wandl UB; Becher R; Kloke O; Nagel-Hiemke M; Moritz T; Beer U; Seeber S; Niederle N
    Blood; 1991 Nov; 78(9):2188-93. PubMed ID: 1932740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential treatment of Ph-positive chronic myeloid leukemia with interferon gamma and interferon alpha.
    Russo D; Fanin R; Zuffa E; Damiani D; Gallizia C; Michieli M; Testoni N; Benfenati D; Visani G; Zaccaria A
    Haematologica; 1990; 75(4):334-9. PubMed ID: 2125966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
    Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
    J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
    Sacchi S; Kantarjian HM; Freireich EJ; O'Brien S; Cortes J; Rios MB; Kornblau S; Giles FJ; Koller C; Gajewski J; Talpaz M
    Leuk Lymphoma; 1999 Nov; 35(5-6):483-9. PubMed ID: 10609785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
    Kantarjian HM; Keating MJ; Estey EH; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
    J Clin Oncol; 1992 May; 10(5):772-8. PubMed ID: 1569449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
    Haematologica; 1992; 77(3):204-14. PubMed ID: 1427426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
    Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
    Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.
    Talpaz M; Kurzrock R; Kantarjian H; Rothberg J; Saks S; Evans L; Gutterman JU
    Cancer; 1991 Nov; 68(10):2125-30. PubMed ID: 1913450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon alfa as primary treatment of chronic myeloid leukemia: long-term follow-up of 71 patients observed in a single center.
    Kloke O; Opalka B; Niederle N
    Leukemia; 2000 Mar; 14(3):389-92. PubMed ID: 10720131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies.
    Freund M; von Wussow P; Diedrich H; Eisert R; Link H; Wilke H; Buchholz F; LeBlanc S; Fonatsch C; Deicher H
    Br J Haematol; 1989 Jul; 72(3):350-6. PubMed ID: 2765403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of interferon-alpha in treatment of chronic myeloid leukemia].
    Thaler J
    Acta Med Austriaca; 1993; 20(3):65-9. PubMed ID: 8368048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia.
    Baccarani M; Rosti G; de Vivo A; Bonifazi F; Russo D; Martinelli G; Testoni N; Amabile M; Fiacchini M; Montefusco E; Saglio G; Tura S;
    Blood; 2002 Mar; 99(5):1527-35. PubMed ID: 11861264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The 6M 12M trial--study of the effectivess and tolerance of treatment in chronic myeloid leukaemia with a combination of interferon alfa and cytarabine].
    Tóthová E; Fricová M; Stecová N; Svorcová E; Guman T; Rraffac S; Kafková A; Hlebasková M
    Vnitr Lek; 2000 Jul; 46(7):391-4. PubMed ID: 15635799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
    Garcia-Manero G; Talpaz M; Giles FJ; Cortes J; Faderl S; O'Brien S; Thomas D; Verstovsek S; Beth Rios M; Shan J; Ferrajoli A; Wierda W; Kantarjian HM
    Cancer; 2003 Jun; 97(12):3010-6. PubMed ID: 12784336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
    O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
    Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-Up of the italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
    Blood; 1998 Sep; 92(5):1541-8. PubMed ID: 9716581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.